Identification of Glycoprotein Biomarkers in Breast Cancer by MALDI

TL;DR

This paper reviews how MALDI mass spectrometry identifies glycoprotein biomarkers in breast cancer, offering insights into disease progression and personalized treatment.

Contribution

The paper provides a comprehensive review of MALDI-based glycoprotein biomarkers in breast cancer, emphasizing their diagnostic and prognostic potential.

Findings

Aberrant glycosylation patterns like hypersialylation and fucosylation are linked to breast cancer progression.

MALDI offers high throughput and spatial resolution for glycoprotein profiling compared to other proteomic methods.

Emerging trends focus on liquid biopsy components like extracellular vesicles for more precise biomarker detection.

Abstract

Protein glycosylation plays a pivotal role in breast cancer biology, influencing cell proliferation, adhesion, migration, and immune evasion. Aberrant N- and O-glycosylation are hallmarks of neoplastic transformation and serve as sensitive indicators of disease progression. This review aims to characterize glycoprotein biomarkers in breast cancer identified using Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry. We examine specific glycosylation alterations—including hypersialylation, fucosylation, and truncated O-glycans—across different molecular subtypes (Luminal A/B, HER2-positive, TNBC) and assess their diagnostic and prognostic potential. Methodologically, the review contrasts MALDI-based profiling and Imaging Mass Spectrometry (MALDI-IMS) with other proteomic techniques, highlighting MALDI’s advantages in throughput and spatial resolution alongside its technical limitations. Furthermore, we discuss emerging frontiers in the field, such as the shift from whole-serum analysis to “liquid biopsy” components (e.g., extracellular vesicles). Ultimately, we argue that implementing quantitative glycoproteomics is essential for advancing personalized oncology.

Figures